FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2016 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced two presentations during the 58th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, CA on December 3rd-6th, 2016.
The two presentations will highlight recent work in re-creating the natural condition of hereditary persistence of fetal hemoglobin (HPFH) that is protective in sickle cell disease and beta thalassemia. The presentations will describe the ability to re-create specific HPFH gene variants in the intended target tissue, human primary CD34+ stem cells, and the effect of these gene variants at re-creating the expression of protective fetal hemoglobin. Additional data on progress towards filing an IND or CTA will also be presented.
“We are excited by our progress and we remain focused on our goal of bringing potentially transformative therapies to patients with beta thalassemia and sickle cell disease,” said Dr. Rodger Novak, CEO of CRISPR Therapeutics. "We look forward to discussing data from our recent work at the upcoming ASH conference.”
Details of the presentations are as follows:
| Title: | CRISPR/Cas9 – Mediated Genome Editing of Human CD34+ Cells Upregulate Fetal Hemoglobin to Clinically Relevant Levels in Single Cell-Derived Erythroid Colonies (Abstract #3623) |
| Presenter: | Bibhu Mishra, Ph.D., (Title)), CRISPR Therapeutics |
| Date: | Monday, December 5, 2016, 6:00-8:00PM PT - Hall GH (San Diego Convention Center) |
| Session: | 112. Thalassemia and Globin Gene Regulation: Poster III |
| Title: | Re-Creating Hereditary Persistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia (Abstract #4708) |
| Presenter: | Bill (Sven Ante) Lundberg, M.D., M.B.A, Chief Scientific Officer, CRISPR Therapeutics |
| Date: | Monday, December 5, 2016, 6:00-8:00PM PT - Hall GH (San Diego Convention Center) |
| Session: | 801. Gene Therapy and Transfer: Poster III |
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform.
MEDIA CONTACTS: Jennifer Paganelli W2O Group for CRISPR 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR 339-970-2843 [email protected]
